OFG
NVO

OmniStar Financial Group’s Novo Nordisk NVO Stock Holding History

OmniStar Financial Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,255
Closed -$647K – 141
2023
Q4 		$647K Buy
6,255
+163
+3% +$16.1K 0.81% 44
2023
Q3 		$556K Sell
6,092
-3,052
-33% -$269K 0.66% 54
2023
Q2 		$740K Buy
9,144
+2,268
+33% +$185K 0.87% 41
2023
Q1 		$547K Sell
6,876
-6,822
-50% -$484K 0.69% 52
2022
Q4 		$927K Buy
13,698
+4,804
+54% +$282K 1.05% 32
2022
Q3 		$443K Buy
8,894
+5,170
+139% +$277K 0.53% 74
2022
Q2 		$207K Sell
3,724
-314
-8% -$17.4K 0.23% 105
2022
Q1 		$224K Sell
4,038
-2,738
-40% -$141K 0.22% 105
2021
Q4 		$379K Buy
6,776
+336
+5% +$18.2K 0.39% 84
2021
Q3 		$309K Buy
+6,440
New +$311K 0.37% 87
2021
Q2 		– Sell
-20,894
Closed -$810K – 156
2021
Q1 		$704K Sell
20,894
-35,206
-63% -$1.25M 0.9% 43
2020
Q4 		$1.96M Buy
56,100
+4,434
+9% +$153K 1.37% 22
2020
Q3 		$1.79M Buy
51,666
+180
+0.3% +$6K 1.35% 24
2020
Q2 		$1.69M Buy
51,486
+2,700
+6% +$86.2K 1.39% 22
2020
Q1 		$1.47M Sell
48,786
-76,838
-61% -$2.29M 1.44% 23
2019
Q4 		$3.64M Sell
125,624
-4,940
-4% -$137K 3.07% 3
2019
Q3 		$3.38M Buy
130,564
+408
+0.3% +$10.3K 2.95% 4
2019
Q2 		$3.32M Buy
130,156
+2,130
+2% +$52.6K 2.98% 2
2019
Q1 		$3.35M Buy
128,026
+54,232
+73% +$1.33M 2.95% 1
2018
Q4 		$1.7M Sell
73,794
-18,576
-20% -$413K 1.73% 19
2018
Q3 		$2.18M Buy
92,370
+602
+0.7% +$14.7K 1.66% 13
2018
Q2 		$2.12M Sell
91,768
-47,678
-34% -$1.13M 2.01% 12
2018
Q1 		$3.44M Sell
139,446
-13,822
-9% -$363K 3.28% 1
2017
Q4 		$4.11M Buy
+153,268
New +$3.9M 3.77% 1

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OmniStar Financial Group's NVO Position: Q1 2024 in Review

OmniStar Financial Group sold out of Novo Nordisk (NVO) in Q1 2024, closing a stake of 6,255 shares — an estimated $647K sold.

OmniStar Financial Group first reported a position in NVO in Q4 2017 and held it in 24 quarters. The position peaked at $4.11M in Q4 2017. 1,744 funds tracked by Wall St. Rank hold NVO as of Q1 2024.

  • OmniStar Financial Group reported no remaining Novo Nordisk position as of Q1 2024 after selling out during the quarter.
  • OmniStar Financial Group sold 6,255 Novo Nordisk shares in Q1 2024, an estimated $647K.
  • OmniStar Financial Group first reported a position in Novo Nordisk in Q4 2017 and held it in 24 quarters.
  • OmniStar Financial Group's Novo Nordisk position peaked at $4.11M in Q4 2017.
  • 1,744 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2024.

Based on OmniStar Financial Group's 13F filing for Q1 2024, filed 23 Apr 2024.